| 4.47 0.11 (2.52%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.38  |
1-year : | 7.46 |
| Resists | First : | 5.46 |
Second : | 6.38 |
| Pivot price | 4.14 |
|||
| Supports | First : | 4.11 |
Second : | 3.26 |
| MAs | MA(5) : | 4.27 |
MA(20) : | 4.05 |
| MA(100) : | 10.39  |
MA(250) : | 14.5 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 71 |
D(3) : | 66 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 29.03 | Low : | 3.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZNTL ] has closed below upper band by 14.1%. Bollinger Bands are 74.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.62 - 4.64 | 4.64 - 4.65 |
| Low: | 4.26 - 4.28 | 4.28 - 4.29 |
| Close: | 4.44 - 4.47 | 4.47 - 4.49 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Thu, 25 Jul 2024
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - Longview News-Journal
Wed, 24 Jul 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL - PR Newswire
Sat, 20 Jul 2024
Entropy Technologies LP Has $277,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Fri, 19 Jul 2024
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Mirae Asset Global Investments Co. Ltd. - Defense World
Wed, 19 Jun 2024
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher - Simply Wall St
Tue, 18 Jun 2024
Investigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLC - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 120.8 (%) |
| Shares Short | 9,620 (K) |
| Shares Short P.Month | 17,510 (K) |
| EPS | -3.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.46 |
| Profit Margin | 0 % |
| Operating Margin | -61.1 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -51.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.57 |
| EBITDA (p.s.) | -2.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -211 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -1.38 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 7.82 |
| Price to Cash Flow | -1.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|